All Stories

  1. Cholecystokinin (CCK): a neuromodulator with therapeutic potential in Alzheimer’s and Parkinson’s disease
  2. O-GlcNAcylation and Its Roles in Neurodegenerative Diseases
  3. Liraglutide Reduces Alcohol Consumption, Anxiety, Memory Impairment, and Synapse Loss in Alcohol Dependent Mice
  4. A Cholecystokinin Analogue Ameliorates Cognitive Deficits and Regulates Mitochondrial Dynamics via the AMPK/Drp1 Pathway in APP/PS1 Mice
  5. Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway
  6. Incretin Mimetics Restore the ER-Mitochondrial Axis and Switch Cell Fate Towards Survival in LUHMES Dopaminergic-Like Neurons: Implications for Novel Therapeutic Strategies in Parkinson’s Disease
  7. A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson’s Disease
  8. Liraglutide reduces alcohol consumption, anxiety, memory impairment, and synapse loss in alcohol dependent mice
  9. Integrated analysis of the lncRNA-associated ceRNA network in Alzheimer's disease
  10. Inhibitory effect of Garlic Powder on MPTP-induced dopaminergic neurodegeneration by activation of Nrf2-HO1 and mitochondrial dynamics
  11. Cholecystokinin Signaling can Rescue Cognition and Synaptic Plasticity in the APP/PS1 Mouse Model of Alzheimer’s Disease
  12. Beyond appetite: Acylated ghrelin as a learning, memory and fear behavior-modulating hormone
  13. DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce α-Synuclein Levels in the 6-OHDA Parkinson’s Disease Rat Model
  14. <italic>MCU</italic> knockdown in hippocampal neurons improves memory performance of an Alzheimer’s disease mouse model
  15. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review
  16. Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases
  17. Cholecystokinin and glucagon-like peptide-1 analogues regulate intestinal tight junction, inflammation, dopaminergic neurons and α-synuclein accumulation in the colon of two Parkinson's disease mouse models
  18. Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson’s disease
  19. Neuroprotective Effects of a Cholecystokinin Analogue in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Parkinson’s Disease Mouse Model
  20. Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research
  21. (D-Ser2) oxyntomodulin recovers hippocampal synaptic structure and theta rhythm in Alzheimer’s disease transgenic mice
  22. A GLP-1/GIP Dual Receptor Agonist DA4-JC Effectively Attenuates Cognitive Impairment and Pathology in the APP/PS1/Tau Model of Alzheimer’s Disease
  23. The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1G93A and TDP-43Q331K transgenic mouse models of ALS
  24. The GLP‐1/GIP dual‐receptor agonist DA5‐CH inhibits the NF‐κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP‐1 single‐receptor agonist NLY01
  25. Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders
  26. Neuroprotective Effects of a GLP-2 Analogue in the MPTP Parkinson’s Disease Mouse Model
  27. Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer’s subjects?
  28. Dehydroabietic acid improves nonalcoholic fatty liver disease through activating the Keap1/Nrf2-ARE signaling pathway to reduce ferroptosis
  29. Incretin mimetics restore the ER-mitochondrial axis and switch neuronal fate towards survival.
  30. Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model
  31. Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease
  32. A GLP-2 Analogue Protects SH-SY5Y and Neuro-2a Cells Against Mitochondrial Damage, Autophagy Impairments and Apoptosis in a Parkinson Model
  33. Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review
  34. Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)
  35. Dehydroabietic acid alleviates high fat diet-induced insulin resistance and hepatic steatosis through dual activation of PPAR-γ and PPAR-α
  36. A GLP-1/GIP/Gcg receptor triagonist improves memory behavior, as well as synaptic transmission, neuronal excitability and Ca2+ homeostasis in 3xTg-AD mice
  37. Driving GABAergic neurons optogenetically improves learning, reduces amyloid load and enhances autophagy in a mouse model of Alzheimer’s disease
  38. Protective Effects of DAla2-GIP-GLU-PAL against Cognitive Deficits and Amyloid Deposition in APP/PS1 AD Mice Associated with Reduction of Neuroinflammation
  39. The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson’s Disease
  40. Magnolol alleviates Alzheimer's disease-like pathology in transgenic C. elegans by promoting microglia phagocytosis and the degradation of beta-amyloid through activation of PPAR-γ
  41. Brain insulin resistance: role in neurodegenerative disease and potential for targeting
  42. GIP has neuroprotective effects in Alzheimer and Parkinson’s disease models
  43. A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice
  44. The novel GLP‐1/GIP analogue DA5‐CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD
  45. Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases
  46. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease
  47. The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke
  48. D‐Ser2‐oxyntomodulin ameliorated Aβ31‐35‐induced circadian rhythm disorder in mice
  49. The novel GLP-1/GIP dual receptor agonist DA3-CH is neuroprotective in the pilocarpine-induced epileptogenesis rat model
  50. Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer’s Disease
  51. DA-JC1 improves learning and memory by antagonizing Aβ31–35-induced circadian rhythm disorder
  52. Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology
  53. Moving towards a more realistic concept of what constitutes Alzheimer's disease
  54. Evidence That Parietal Lobe Fatty Acids May Be More Profoundly Affected in Moderate Alzheimer’s Disease (AD) Pathology Than in Severe AD Pathology
  55. The Novel DA–CH3 Dual Incretin Restores Endoplasmic Reticulum Stress and Autophagy Impairments to Attenuate Alzheimer-Like Pathology and Cognitive Decrements in the APPSWE/PS1ΔE9 Mouse Model
  56. Prolonged Drug-Releasing Fibers Attenuate Alzheimer’s Disease-like Pathogenesis
  57. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model
  58. Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced depression model via improving hippocampal neural plasticity
  59. Are Alzheimer's disease and other neurodegenerative disorders caused by impaired signalling of insulin and other hormones?
  60. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models
  61. DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer's disease
  62. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease
  63. Post-treatment with the GLP-1 analogue liraglutide alleviate chronic inflammation and mitochondrial stress induced by Status epilepticus
  64. The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease
  65. A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease
  66. GLP-1 receptor agonists show neuroprotective effects in animal models of diabetes
  67. Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease
  68. Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells
  69. A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease
  70. Integrating microRNA and messenger RNA expression profiles in a rat model of deep vein thrombosis
  71. Therapeutic Potential of Baicalein in Alzheimer’s Disease and Parkinson’s Disease
  72. Metabolomic Profiling of Bile Acids in Clinical and Experimental Samples of Alzheimer’s Disease
  73. A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model
  74. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease
  75. D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation
  76. Lixisenatide attenuates the detrimental effects of amyloid β protein on spatial working memory and hippocampal neurons in rats
  77. Therapeutic potential of flavonoids in spinal cord injury
  78. Levo-tetrahydropalmatine inhibits the acquisition of ketamine-induced conditioned place preference by regulating the expression of ERK and CREB phosphorylation in rats
  79. A Novel Bioresorbable Device as a Controlled Release System for Protecting Cells from Oxidative Stress from Alzheimer’s Disease
  80. Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases
  81. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide analogues as novel treatments for Alzheimer’s and Parkinson’s disease
  82. Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells
  83. Therapeutic Potential of Genipin in Central Neurodegenerative Diseases
  84. A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson’s disease by reducing chronic inflammation in the brain
  85. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson′s disease by increasing expression of BNDF
  86. Alzheimer's disease–like pathology has transient effects on the brain and blood metabolome
  87. Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model
  88. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology
  89. A novel dual-glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat
  90. Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer’s disease
  91. Neuroprotective role of (Val8) GLP-1-Glu-PAL in an in vitro model of Parkinson′s disease
  92. Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease
  93. Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson’s disease mouse model
  94. Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice
  95. Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease
  96. Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease
  97. GLIA Bilbao 2015: Abstracts Oral Presentations, Posters, Indexes
  98. Untargeted Metabolomic Analysis of Human Plasma Indicates Differentially Affected Polyamine and L-Arginine Metabolism in Mild Cognitive Impairment Subjects Converting to Alzheimer’s Disease
  99. Quantitative Measurement of [Na+] and [K+] in Postmortem Human Brain Tissue Indicates Disturbances in Subjects with Alzheimer's Disease and Dementia with Lewy Bodies
  100. Restoration of Cerebral and Systemic Microvascular Architecture in APP/PS1 Transgenic Mice Following Treatment with Liraglutide™
  101. Neuroprotective effects of geniposide on Alzheimer’s disease pathology
  102. Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice
  103. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease
  104. Age-Associated Changes of Brain Copper, Iron, and Zinc in Alzheimer's Disease and Dementia with Lewy Bodies
  105. Increased number of orexin/hypocretin neurons with high and prolonged external stress-induced depression
  106. Lixisenatide rescues spatial memory and synaptic plasticity from amyloid β protein-induced impairments in rats
  107. Peptide drugs that have been developed to treat type 2 diabetes show neuroprotective effects
  108. Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases
  109. Neural Circuit Interactions between the Dorsal Raphe Nucleus and the Lateral Hypothalamus: An Experimental and Computational Study
  110. Editorial
  111. First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer's disease
  112. The incretin hormones glucagonlike peptide 1 and glucose‐dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease
  113. New drug treatments show neuroprotective effects in Alzheimer′s and Parkinson′s diseases
  114. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease
  115. Metabolic signatures of human Alzheimer’s disease (AD): 1H NMR analysis of the polar metabolome of post-mortem brain tissue
  116. TNF-α Mediates PKR-Dependent Memory Impairment and Brain IRS-1 Inhibition Induced by Alzheimer’s β-Amyloid Oligomers in Mice and Monkeys
  117. Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress
  118. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
  119. Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence
  120. D-Ala2GIP Facilitated Synaptic Plasticity and Reduces Plaque Load in Aged Wild Type Mice and in an Alzheimer's Disease Mouse Model
  121. 1H NMR metabolomics investigation of an Alzheimer’s disease (AD) mouse model pinpoints important biochemical disturbances in brain and plasma
  122. Chronic Treatment with the GLP1 Analogue Liraglutide Increases Cell Proliferation and Differentiation into Neurons in an AD Mouse Model
  123. Cell signalling and diabetes
  124. Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats
  125. A Novel Retro-Inverso Peptide Inhibitor Reduces Amyloid Deposition, Oxidation and Inflammation and Stimulates Neurogenesis in the APPswe/PS1ΔE9 Mouse Model of Alzheimer’s Disease
  126. Val8-GLP-1 remodels synaptic activity and intracellular calcium homeostasis impaired by amyloid β peptide in rats
  127. Investigation of the Human Brain Metabolome to Identify Potential Markers for Early Diagnosis and Therapeutic Targets of Alzheimer’s Disease
  128. New animal models of Alzheimer’s disease that display insulin desensitization in the brain
  129. Neuroprotective effects of D-Ala2GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model
  130. The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain
  131. The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer’s disease
  132. Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection
  133. The Diabetes Drug Liraglutide Ameliorates Aberrant Insulin Receptor Localisation and Signalling in Parallel with Decreasing Both Amyloid-β Plaque and Glial Pathology in a Mouse Model of Alzheimer’s Disease
  134. Effects of the glucagon-like polypeptide-1 analogue (Val8)GLP-1 on learning, progenitor cell proliferation and neurogenesis in the C57B/16 mouse brain
  135. Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice
  136. Roles of Glucagon-Like Peptide and Glucose-Dependent Insolinotropic Polypeptide Hormones in Brain Function and Neurodegeneration
  137. Actions of incretin metabolites on locomotor activity, cognitive function and in vivo hippocampal synaptic plasticity in high fat fed mice
  138. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomers
  139. The effect of ageing on neurogenesis and oxidative stress in the APPswe/PS1deltaE9 mouse model of Alzheimer's disease
  140. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
  141. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice
  142. (Val8) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains
  143. Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice
  144. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease
  145. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease
  146. The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease
  147. Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis
  148. Hepcidin Treatment Modulates the Expression of Divalent Metal Transporter-1, Ceruloplasmin, and Ferroportin-1 in the Rat Cerebral Cortex and Hippocampus
  149. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain
  150. Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice
  151. Val8-glucagon-like peptide-1 protects against Aβ1–40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats
  152. New roles for insulin-like hormones in neuronal signalling and protection: New hopes for novel treatments of Alzheimer’s disease?
  153. Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance
  154. Incretin Analogues that have been Developed to Treat Type 2 Diabetes Hold Promise as a Novel Treatment Strategy for Alzheimers Disease
  155. Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet
  156. Synaptic Plasticity in the Hippocampus of a APP/PS1 Mouse Model of Alzheimer's Disease Is Impaired in Old but Not Young Mice
  157. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease
  158. The effect of mGlu8deficiency in animal models of psychiatric diseases
  159. The Role of GLP-1 in Neuronal Activity and Neurodegeneration
  160. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease
  161. Quantitative analysis of iron concentration and expression of ferroportin 1 in the cortex and hippocampus of rats induced by cerebral ischemia
  162. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system
  163. Seems familiar
  164. Coexistences of insulin signaling-related proteins and choline acetyltransferase in neurons
  165. Information Processing by Neuronal Populations
  166. Distributed population codes in sensory and memory representations of the neocortex
  167. Functional roles of theta and gamma oscillations in the association and dissociation of neuronal networks in primates and rodents
  168. Summary of chapters, conclusion, and future targets
  169. Theta rhythm and bidirectional plasticity in the hippocampus
  170. Anaesthesia generates neuronal insulin resistance by inducing hypothermia
  171. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid
  172. Protease-Resistant Glucose-Dependent Insulinotropic Polypeptide Agonists Facilitate Hippocampal LTP and Reverse the Impairment of LTP Induced by Beta-Amyloid
  173. Common pathological processes in Alzheimer disease and type 2 diabetes: A review
  174. Soluble beta-amyloid[25–35] reversibly impairs hippocampal synaptic plasticity and spatial learning
  175. Impairments of hippocampal synaptic plasticity induced by aggregated beta-amyloid (25–35) are dependent on stimulation-protocol and genetic background
  176. Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
  177. Inactivation of the rat dorsal striatum impairs performance in spatial tasks and alters hippocampal theta in the freely moving rat
  178. Lack of the metabotropic glutamate receptor subtype 7 selectively modulates Theta rhythm and working memory
  179. Rats are able to navigate in virtual environments
  180. Development of Beta-Amyloid-induced Neurodegeneration in Alzheimer's Disease and Novel Neuroprotective Strategies
  181. Lack of the metabotropic glutamate receptor subtype 7 selectively impairs short-term working memory but not long-term memory
  182. Learned association of allocentric and egocentric information in the hippocampus
  183. Perirhinal cortex neuronal activity related to long-term familiarity memory in the macaque
  184. Reward modulates neuronal activity in the hippocampus of the rat
  185. Time, Space and Hippocampal Functions
  186. Different strains of rats show different sensitivity to block of long-term potentiation by nitric oxide synthase inhibitors
  187. Metabotropic glutamate receptors control gating of spike transmission in the hippocampus area CA1
  188. Perirhinal Cortex Neuronal Activity is Actively Related to Working Memory in the Macaque
  189. Neuronal Mechanisms of Memory Formation
  190. Conclusions and Future Targets
  191. Introduction: Long-Term Potentiation as a Model for Memory Mechanisms: The Story So Far
  192. Theta-Facilitated Induction of Long-Term Potentiation: A Better Model for Memory Formation?
  193. Consciousness in mind: a correlate for ACh?
  194. Synaptic plasticity and learning and memory: LTP and beyond
  195. Synaptic plasticity and learning and memory: LTP and beyond
  196. Retraction
  197. Stress impairs performance in spatial water maze learning tasks
  198. Metabotropic glutamate receptor activation and blockade: their role in long-term potentiation, learning and neurotoxicity
  199. Nitric oxide is required for expression of LTP that is induced by stimulation phase-locked with theta rhythm
  200. Possible Causes of Alzheimer's Disease: Amyloid Fragments, Free Radicals, and Calcium Homeostasis
  201. b-amyloid induced reduction in synaptic transmission is reversed by inhibitors of nitric oxide synthase
  202. Glucocorticoid receptor and protein/RNA synthesis-dependent mechanisms underlie the control of synaptic plasticity by stress
  203. Block of theta-burst-induced long-term potentiation by (1S,3S)-1-aminocyclopentane-1,3-dicarboxylic acid: further evidence against long-term potentiation as a model for learning
  204. Nitric oxide, the enigmatic neuronal messenger: its role in synaptic plasticity
  205. HFS-induced long-term potentiation and LFS-induced depotentiation in area CA1 of the hippocampus are not good models for learning
  206. Activation of group-II metabotropic glutamate receptors blocks induction of long-term potentiation and depotentiation in area CA1 of the rat in vivo
  207. Block of HFS-induced LTP in the dentate gyrus by 1S,3S-ACPD
  208. Long-term potentiation: A good model for learning and memory?
  209. l-AP4 (l-(+)-2-amino-4-phosphonobutyric acid) induced impairment of spatial learning in the rat is antagonized by MAP4 ((S)-2-amino-2methyl-4-phosphonobutanoic acid)
  210. 7-Nitro indazole, a selective neuronal nitric oxide synthase inhibitor in vivo, impairs spatial learning in the rat.
  211. Training in the Morris water maze occludes the synergism between ACPD and arachidonic acid on glutamate release in synaptosomes prepared from rat hippocampus.
  212. Prostaglandins play a role in memory consolidation in the chick
  213. Inhibitors of Cyclooxygenases produce Amnesia for a Passive Avoidance Task in the Chick
  214. Quinacrine Acts like an Acetylcholine Receptor Antagonist Rather Than like a Phospholipase A2 Inhibitor in a Passive Avoidance Task in the Chick
  215. Inhibitors of PLA2 and NO synthase cooperate in producing amnesia of a spatial task
  216. Two retrograde messengers are better than one?
  217. Quinolinic acid lesion of the rat entorhinal cortex pars medialis produces selective amnesia in allocentric working memory (WM), but not in egocentric WM
  218. Inhibitors of metabotropic glutamate receptors produce amnestic effects in chicks
  219. Inhibitors of phospholipase A2 produce amnesia for a passive avoidance task in the chick
  220. Inhibiting synthesis of the putative retrograde messenger nitric oxide results in amnesia in a passive avoidance task in the chick
  221. An inhibitor of nitric oxide synthesis prevents memory formation in the chick
  222. How could populations of neurons encode information?